Furthermore, numbers of tumour reactive CXCL13+ CD8+ T cells were increased following anti-PD-1 treatment, indicating that expansion of this population is a hallmark of anti-cancer immunity (7–9). The gene discussed is CXCL13; the disease is neoplasm.